Published in Science on March 19, 1993
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A (1993) 4.49
Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest (2008) 4.30
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci U S A (2000) 3.95
CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol (1996) 3.39
A Blueprint for HIV Vaccine Discovery. Cell Host Microbe (2012) 3.27
Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol (1998) 3.14
Molecular biology of pseudorabies virus: impact on neurovirology and veterinary medicine. Microbiol Mol Biol Rev (2005) 3.06
Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol (2001) 3.05
Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med (1998) 2.84
Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol (1998) 2.82
Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med (1997) 2.81
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev (1996) 2.77
Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A (1994) 2.58
Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A (1994) 2.58
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A (2005) 2.57
Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. J Clin Invest (1994) 2.57
CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev (2006) 2.49
A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol (2005) 2.44
Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis (2007) 2.36
Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A (1993) 2.35
Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J Exp Med (1998) 2.31
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A (1997) 2.20
Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med (1996) 2.18
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol (1996) 2.15
Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun (1998) 2.12
A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol (2008) 2.10
Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol (2013) 2.09
The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype. J Virol (2002) 2.05
Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis (2010) 2.05
Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci U S A (1996) 2.02
Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A (1996) 2.01
Vaccination strategies for mucosal immune responses. Clin Microbiol Rev (2001) 1.98
Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J Virol (1993) 1.92
Human herpesviruses in the cornea. Br J Ophthalmol (2000) 1.90
DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis (2002) 1.88
Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect (2008) 1.88
CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest (1998) 1.87
Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol (2007) 1.87
DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J Virol (1995) 1.83
Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol (1998) 1.82
Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med (1997) 1.81
Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol (2001) 1.81
Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol (1996) 1.80
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol (2005) 1.78
Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol (2004) 1.78
Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol (2011) 1.74
Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS One (2007) 1.72
Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol (1996) 1.71
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One (2011) 1.71
Generation of monoclonal antibodies against human prion proteins in PrP0/0 mice. Mol Med (1996) 1.68
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65
Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A (2000) 1.63
TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J Immunol (2011) 1.61
Vaccines: the fourth century. Clin Vaccine Immunol (2009) 1.61
DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci U S A (1995) 1.60
Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob Agents Chemother (1996) 1.58
DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol (1999) 1.57
Protective role of gamma interferon during the recall response to influenza virus. J Virol (1998) 1.55
Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med (1997) 1.53
DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol (2005) 1.52
Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology (1996) 1.52
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine (2008) 1.51
Retracted Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model. Proc Natl Acad Sci U S A (2000) 1.51
Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A (2000) 1.50
Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P. Proc Natl Acad Sci U S A (1998) 1.50
DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J Virol (1998) 1.49
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol (2012) 1.49
Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology (1995) 1.46
Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact (2011) 1.45
Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine (2007) 1.45
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer (2004) 1.45
Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest (1997) 1.44
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine (2008) 1.43
Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J (2010) 1.39
Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J Virol (1997) 1.38
Hepatitis C: progress and problems. Clin Microbiol Rev (1994) 1.37
Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest (2004) 1.37
Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol (2002) 1.36
Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol (1997) 1.36
B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J Immunol (2008) 1.35
Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol (2011) 1.35
Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immun (2005) 1.34
DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol (1998) 1.34
DNA vaccination against persistent viral infection. J Virol (1995) 1.33
Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect Immun (1998) 1.31
Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med (2007) 1.30
Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol (1996) 1.29
Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog (2013) 1.28
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther (2003) 1.28
DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity. Proc Natl Acad Sci U S A (1997) 1.27
Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J Virol (1997) 1.27
Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine (2007) 1.26
Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol (1998) 1.25
Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol (1995) 1.25
Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A (1994) 1.25
Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J Virol (1998) 1.23
In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol (1999) 1.23
Direct gene transfer into mouse muscle in vivo. Science (1990) 10.39
Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med (1996) 5.38
Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol (1994) 4.07
Functional antagonism between c-Jun and MyoD proteins: a direct physical association. Cell (1992) 3.55
Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature (1998) 3.46
Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem (1994) 3.41
Muscle-specific transcriptional activation by MyoD. Genes Dev (1991) 3.37
cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. Proc Natl Acad Sci U S A (1989) 3.09
Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A (1994) 2.58
Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med (1995) 2.58
Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A (1989) 2.55
Pharmacoeconomics of antibacterial treatment. Pharmacoeconomics (1992) 2.51
The major and minor group receptor families contain all but one human rhinovirus serotype. Virology (1991) 2.50
Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. J Neurosurg (2001) 2.27
Slow inactivation of Na+ current and slow cumulative spike adaptation in mouse and guinea-pig neocortical neurones in slices. J Physiol (1996) 2.07
T lymphocyte line specific for thyroglobulin produces or vaccinates against autoimmune thyroiditis in mice. J Immunol (1983) 2.05
Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol (1993) 2.05
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord (1987) 1.92
Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol (1998) 1.82
Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin. Eur J Immunol (1993) 1.82
Foreign body in the airway. A review of 200 cases. Am J Dis Child (1980) 1.82
Phosphorylation of the C terminus of Fos protein is required for transcriptional transrepression of the c-fos promoter. Nature (1990) 1.81
Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med (1997) 1.81
Blood-brain barrier disruption results in delayed functional and structural alterations in the rat neocortex. Neurobiol Dis (2006) 1.73
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Adv Neurol (1988) 1.72
A rapid infusion protocol is safe for total dose iron polymaltose: time for change. Intern Med J (2011) 1.70
The role of the CCAAT/enhancer-binding protein in the transcriptional regulation of the gene for phosphoenolpyruvate carboxykinase (GTP). Mol Cell Biol (1990) 1.67
Regenerative activity in apical dendrites of pyramidal cells in neocortex. Cereb Cortex (1993) 1.66
Intracellular delivery of proteins with a new lipid-mediated delivery system. J Biol Chem (2001) 1.65
Delayed hypersensitivity in Graves' disease and exophthalmos: identification of thyroglobulin in normal human orbital muscle. Endocrinology (1977) 1.64
Galloway-Mowat syndrome of abnormal gyral patterns and glomerulopathy. Am J Med Genet (1993) 1.64
Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A (2001) 1.63
Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther (1995) 1.60
Negative and positive regulation by transcription factor cAMP response element-binding protein is modulated by phosphorylation. Proc Natl Acad Sci U S A (1990) 1.60
Iron in parkinsonian and control substantia nigra--a Mössbauer spectroscopy study. Mov Disord (1996) 1.57
Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol (2001) 1.57
Neutralization-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein. J Virol (1990) 1.55
Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine (1995) 1.53
Isoflurane--a powerful coronary vasodilator in patients with coronary artery disease. Anesthesiology (1983) 1.53
Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110. Proc Natl Acad Sci U S A (1989) 1.52
Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology (1996) 1.52
Blood-brain barrier disruption in post-traumatic epilepsy. J Neurol Neurosurg Psychiatry (2007) 1.51
Anti-hypervariable region antibody induced by a defined peptide: an approach for studying the structural correlates of idiotypes. Proc Natl Acad Sci U S A (1984) 1.50
Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum Gene Ther (1995) 1.49
Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol (2000) 1.48
Preliminary results of a liver allocation plan using a continuous medical severity score that de-emphasizes waiting time. Liver Transpl (2001) 1.46
Regulation of endothelin-1 expression in the bovine corpus luteum: elevation by prostaglandin F 2 alpha. Endocrinology (1996) 1.45
Nomenclature for synthetic gene delivery systems. Hum Gene Ther (1997) 1.44
A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci U S A (1996) 1.44
The role of preserved autogenous cartilage graft in septorhinoplasty. Ann Plast Surg (1994) 1.43
Risk of intracranial aneurysms in families with subarachnoid hemorrhage. Can J Neurol Sci (1995) 1.43
Framing pictures: the role of knowledge in automatized encoding and memory for gist. J Exp Psychol Gen (1979) 1.41
The mononuclear response to intrapleural injection in the rat. J Pathol Bacteriol (1966) 1.40
The V5A13.1 envelope glycoprotein deletion mutant of mouse hepatitis virus type-4 is neuroattenuated by its reduced rate of spread in the central nervous system. Virology (1992) 1.39
Gene therapeutics. Nature (1991) 1.39
Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J Virol (1997) 1.38
Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Immunol (1990) 1.36
Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine (2000) 1.34
Early psychosocial risks for adolescent suicidal ideation and attempts. J Am Acad Child Adolesc Psychiatry (1995) 1.32
Psychological functioning in children and adolescents with Sturge-Weber syndrome. J Child Neurol (2000) 1.32
Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine (1994) 1.30
Effectiveness of resistive heating compared with passive warming in treating hypothermia associated with minor trauma: a randomized trial. Mayo Clin Proc (2001) 1.27
Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol (2000) 1.26
Hyperpotentiation by synthetic double-stranded RNA of antibody responses to influenza virus vaccine in adjuvant 65. Proc Soc Exp Biol Med (1969) 1.26
Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol (1993) 1.24
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol (2013) 1.24
Distress, denial, and low adherence to behavioral interventions predict faster disease progression in gay men infected with human immunodeficiency virus. Int J Behav Med (1994) 1.23
The glycine-alanine repeating region is the major epitope of the Epstein-Barr nuclear antigen-1 (EBNA-1). J Immunol (1987) 1.22
Purification of a hexokinase-binding protein from the outer mitochondrial membrane. J Biol Chem (1979) 1.21
Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%). Crit Care Med (1980) 1.20
Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology (2007) 1.19
Utilization of genomic sequence information to develop malaria vaccines. J Exp Biol (2003) 1.19
Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood (1980) 1.18
Electron microscopy of human cytomegalovirus DNA. Arch Virol (1976) 1.18
Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. J Med Chem (1985) 1.18
LFA-1 membrane molecule in the regulation of homotypic adhesions of human B lymphocytes. J Immunol (1985) 1.18
Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice. J Exp Med (1988) 1.16
Stepwise repolarization from Ca2+ plateaus in neocortical pyramidal cells: evidence for nonhomogeneous distribution of HVA Ca2+ channels in dendrites. J Neurosci (1993) 1.15
DNA of human Raji target cells is damaged upon lymphocyte-mediated lysis. J Immunol (1986) 1.15
Antibody responses to capsular polysaccharide backbone and O-acetate side groups of Streptococcus pneumoniae type 9V in humans and rhesus macaques. Infect Immun (1998) 1.14
Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. Proc Natl Acad Sci U S A (1997) 1.13
Transcription and replication of vesicular stomatitis virus: effects of temperature-sensitive mutations in complementation group IV. J Virol (1974) 1.13
Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine (1994) 1.11